# A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

Source: https://onco.cc/trials/nct07659795/  
OnCo record `nct07659795` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of VS-7375, Cetuximab, Panitumumab in colorectal cancer, run by Verastem, Inc., now recruiting.

## Summary

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer is a phase 2 interventional study registered as NCT07659795 by Verastem, Inc., with 150 participants planned, started 2026-07-28 and due to reach its primary completion in 2027-06. Interventions recorded: VS-7375, cetuximab, panitumumab, Cetuximab + mFOLFOX6. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07659795
- Phase: 2
- Setting: A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)
- Sponsor: Verastem, Inc.
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT07659795: https://clinicaltrials.gov/study/NCT07659795

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Cetuximab](https://onco.cc/drugs/cetuximab/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Panitumumab](https://onco.cc/drugs/panitumumab/), [VS-7375](https://onco.cc/drugs/vs-7375/)
- companies: [Verastem Oncology](https://onco.cc/companies/verastem/)

---
JSON: https://onco.cc/api/v1/entities/nct07659795.json